home / lobbying / lobbying_activities

lobbying_activities: 838870

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id filing_uuid filing_type registrant_name registrant_id client_name filing_year filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
838870 98366d13-ebfd-4162-ac71-86b20ca44c9c Q3 AMERICAN PHARMACISTS ASSOCIATION 3071 AMERICAN PHARMACISTS ASSOCIATION 2009 third_quarter PHA HR1204 - The Community Pharmacy Fairness Act of 2009 S80 - Pharmaceutical Market Access Act of 2009 HR1298/S525 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR163 - Prescription Drug Affordability Act HR2400 - Strategies to Address Antimicrobial Resistance Act HR1706 - Protecting Consumer Access to Generic Drugs Act of 2009 HR3018 - Amend the Controlled Substance Act to address the use of intrathecal pumps (Docket Number: FDA-2008-P-0380) Citizen Petition: Requesting a FDA Action on a "One Document Solution" for all Pharmacy-Based Communications (Docket Number FDA2008N0038) Risk Communication Advisory Committee; Notice of Meeting on the types of communications that patients receive at the pharmacy includes: medication guides; patients package inserts; and consumer medication information (Docket Number FDA2009D0181) Draft Guidance for Industry on Label Comprehension Studies for Nonprescription Drug Products;Availability (Docket Number FDA2009N0295) Providing Effective Information to Consumers About Prescription Drug Risks and Benefits; Public Workshop (Docket Number FDA1977N0013) (formerly Docket No. 1977N0094L) Organ-Specific Warnings; Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use; Final Monograph (Docket Number FDA2009N0143) Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public Meeting (Docket Number FDA2006N0238) (formerly Docket No. 2006N0062) Expanded Access to Investigational Drugs for Treatment Use (Docket Number FDA2006N0237) (formerly Docket No. 2006N0061) Charging for Investigational Drugs Under an Investigational New Drug Application (Docket Number FDA2009N0247) Food and Drug Administration Transparency Task Force; Reopening of Comment Period (Docket Number DEA321a) Identification of Institution-based Individual Practitioners (Docket Number FDA2009N0374) Educating the Public About Removal of Essential-Use Designation for Epinephrine; Public Workshop; Request for Comments (Docket Number FDA2009N0441) Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet and Social Media Tools; Notice of Public Hearing (Docket Number FDA-2009-N-0138) Liver Injury Related to the Use of Acetaminophen; Joint Meeting of the Drug Safety and Risk Management Advisory Committee, Nonprescription Drugs Advisory Committee and the Anesthetic and Life Support Drugs Advisory Committee (DEA Information Collection 1117-0046) Self-Certification, Training and Logbooks for Regulated Sellers of Scheduled Listed Chemical Products Concept - Oppose Liberalizing Prescription Drug Importation Concept - Misuse of Antibiotics in Agriculture Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Indian Health Service,SENATE,White House Office   157696 0 0 2009-10-19T15:08:10-04:00
Powered by Datasette · Queries took 4.213ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API